Brugada syndrome: from cell to bedside.
Since its introduction as a new clinical entity in 1992, the Brugada syndrome has attracted great interest because of its high incidence in many parts of the world and its association with high risk for sudden death in infants, children, and young adults. Recent years have witnessed an exponential rise in the number of reported cases and a striking proliferation of articles serving to define the clinical, genetic, cellular, ionic, and molecular aspects of the disease. A consensus report published in 2002 delineated diagnostic criteria for the syndrome. A second consensus conference was held in September 2003. This review provides an in-depth overview of the clinical, genetic, molecular, and cellular aspects of the Brugada syndrome, incorporating the results of the two consensus conferences, and the numerous clinical and basic publications on the subject. The proposed terminology, diagnostic criteria, risk stratification schemes, and device and pharmacologic approach to therapy discussed are based on available clinical and basic studies and should be considered a work-in-progress that will without doubt require fine-tuning as confirmatory data from molecular studies and prospective trials become available.
Antzelevitch
Charles
C
Masonic Medical Research Laboratory, Utica, NY 13501, USA. ca@mmrl.edu
Brugada
Pedro
P
Brugada
Josep
J
Brugada
Ramon
R
D019571:Arrhythmogenic Right Ventricular Dysplasia / Q000209:etiology / Q000503:physiopathology; D002037:Bundle-Branch Block / Q000150:complications / Q000151:congenital / Q000175:diagnosis / Q000453:epidemiology / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy; D003937:Diagnosis, Differential; D004562:Electrocardiography; D020022:Genetic Predisposition to Disease; D006801:Humans; D010641:Phenotype; D015995:Prevalence; D012307:Risk Factors; D017678:Sex Distribution; D012737:Sex Factors; D013577:Syndrome; D017180:Tachycardia, Ventricular / Q000209:etiology / Q000503:physiopathology